Companies › Taizhou Mabtech Pharmaceutical
5 active drug programs in 28 registered trials: 10 Phase 4, 9 Phase 2, 5 Phase 1, 4 Phase 3; Oncology, Immunology, Gastroenterology, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Infliximab TNF-alpha inhibitor | TNF | Phase 4 | Crohn Disease; Inflammatory Bowel Diseases; Ulcerative Colitis; Schizophrenia … | Nov 2026 |
| Enlituo® EGFR inhibitor monoclonal antibody | EGFR | Phase 3 | Colorectal Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Oct 2029 |
| Omalizumab (CMAB007) Ig epsilon chain C region inhibitor | IGHE | Phase 3 | Chronic Spontaneous Urticaria | – |
| CMAB017 | – | Phase 1 | Solid Malignancies | May 2027 |
| CMAB015 Interleukin-17A (IL-17A) inhibitor monoclonal antibody | IL17A | Phase 1 | Psoriasis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06059989 | Infliximab | Phase 3 | Inflammatory Disease | Immunology | Jun 2025 |
| NCT06365879 | Omalizumab (CMAB007) | Phase 3 | Chronic Spontaneous Urticaria | Immunology | Jan 2026 |
| NCT07254325 | CMAB015 | Phase 1 | Psoriasis | Immunology | Jun 2026 |
| NCT04835506 | Infliximab | Phase 4 | Crohn Disease | Immunology | Sep 2026 |
| NCT03819296 | Infliximab | Phase 1 | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Oncology | Oct 2026 |
| NCT05906576 | Infliximab | Phase 4 | Crohn Disease | Immunology | Nov 2026 |
| NCT06113913 | Infliximab | Phase 4 | Inflammatory Bowel Diseases | Immunology | Nov 2026 |
| NCT03684278 | Infliximab | Phase 2 | Acute Pancreatitis | Gastroenterology | Dec 2026 |
| NCT05043870 | Infliximab | Phase 4 | Crohn Disease | Immunology | Dec 2026 |
| NCT04999228 | Infliximab | Phase 4 | Ulcerative Colitis | Immunology | Dec 2026 |
| NCT05689879 | Infliximab | Phase 3 | Sarcoidosis | Immunology | Jan 2027 |
| NCT05180994 | Infliximab | Phase 1 | Glaucoma Following Surgery | Ophthalmology | Mar 2027 |
| NCT05660746 | Infliximab | Phase 2 | Crohn Disease | Immunology | Mar 2027 |
| NCT06933069 | CMAB017 | Phase 1 | Solid Malignancies | Oncology | May 2027 |
| NCT06051253 | Infliximab | Phase 4 | Crohn Disease | Immunology | Jun 2027 |
| NCT05034536 | Infliximab | Phase 2 | Metastatic Melanoma | Oncology | Jun 2027 |
| NCT05169593 | Infliximab | Phase 4 | Crohn Disease | Immunology | Oct 2027 |
| NCT04407247 | Infliximab | Phase 1 | Colitis | Oncology | Dec 2027 |
| NCT05823532 | Infliximab | Phase 4 | Schizophrenia | Psychiatry | Mar 2028 |
| NCT06453317 | Infliximab | Phase 2 | Ulcerative Colitis | Immunology | Apr 2028 |
| NCT06453317 | Infliximab | Phase 2 | Ulcerative Colitis | Immunology | Apr 2028 |
| NCT06136546 | Infliximab | Phase 2 | Depressive Disorder, Major | Psychiatry | Aug 2028 |
| NCT07683975 | Infliximab | Phase 4 | Acute Kidney Injury | Genitourinary | Jan 2029 |
| NCT02714634 | Infliximab | Phase 4 | Rheumatoid Arthritis | Immunology | Mar 2029 |
| NCT07595276 | Enlituo® | Phase 3 | Colorectal Cancer | Oncology | Oct 2029 |
| NCT04305145 | Infliximab | Phase 2 | Melanoma Stage III | Oncology | Jun 2030 |
| NCT07791745 | Enlituo® | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Oncology | Aug 2032 |
| NCT07791745 | Enlituo® | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Oncology | Aug 2032 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Johnson & Johnson (Janssen) Dizal Pharmaceuticals Chia Tai Tianqing Pharmaceutical Group Betta Pharmaceuticals Novartis Jiangsu Hansoh Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
Tanabe Pharma Beijing VDJBio Jiangsu Aosaikang Pharmaceutical Ganzhou Hemay Pharmaceutical Celltrion
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.